Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RPA - Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Company: Alvotech Holdings S.A Date: 2025-08-06 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

# Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

**REYKJAVIK, ICELAND (August 6, 2025)** – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025.  Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).  Live audio of the conference call will be webcast and available on Alvotech’s investor portal.

Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor portal [https://investors.alvotech.com](https://www.globenewswire.com/Tracker?data=iuwRp185Aeb1iYipCn3lh76zQYCd4jrKbM7UToBl6D17JJgAROorcPF7N6mM5nyO0NdbfZtU-u4iqdYDtx2fKe2gxctlgYRqKObyKE4ijkkDlFtywevAnG2cVRyprIry). Specifically, links to access the webcast and instructions to sign in by phone can be found at [https://investors.alvotech.com/events/event-details/q2-2025-earnings](https://www.globenewswire.com/Tracker?data=iuwRp185Aeb1iYipCn3lh76zQYCd4jrKbM7UToBl6D0B8f77uMpK5vSCY2MTPe4K5A03opujG0Ro5prVbOIQPC75181diwJHrHp1x8RCw6--fd3f2PIQ3HNsKnj4OWApZ7z5sq_7ST4YNZWkZ747Luaveas8B_5XYgIvufpzpUaPpow7LkelSpOq-WtQNw0etlKgK12EdLaf5ZIKOUH7oMuaRwBiMlxrMnMiMRwmi8s=). The webcast will also be archived and available for replay for 90 days after the event.

**About Alvotech**  

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit [https://www.alvotech.com](https://www.globenewswire.com/Tracker?data=iuwRp185Aeb1iYipCn3lh1VCZ9e_Z4XI8R_CNDy0aYhOpz_Zf0QL2G6pGAVI8AUO2FZNjPEesvHWlEEr8xnzDWQHcpQwMmUSB9gUHts0nME=). None of the information on the Alvotech website shall be deemed part of this press release.

**ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS**  

Benedikt Stefansson, VP  

[alvotech.ir@alvotech.com](https://www.globenewswire.com/Tracker?data=3OVCEiB1qSN0_CGJgusExBYrrjQo6NPatvQ92_Ev7CvU22dVGydVyHZ2mI0sOTCOELaDxRz1DGOnObQ2IGtjOFIdb-HyB9FJh5FfeGaCC-qVLfXixqx-5Ml4TrojNsX_)

Please visit our [investor portal](https://www.globenewswire.com/Tracker?data=QFvDZaRcDImXSZHUYxA92kAoNhwWCbIlM3guJb9b3bUklgD6xmVecMPo0HuZjW4wyMHLMHA1C87tLNzuQ9XRS2KV3L9GxQGMSUu5Wohtu7s=), and our [website](https://www.globenewswire.com/Tracker?data=f2iC87MtlHDa8U0v3n6bGdo3JuQz0KEcpW1BWvMgW4-ObSEUdZ7XplraKCyhGn8Rlf76tsN36yQt2gBzaOdsiw==) or follow us on social media on [LinkedIn](https://www.globenewswire.com/Tracker?data=-dwh78DnSxwg8sM-yKA_ESPcmupC1q77wWbEWzEU4yD_0ziqII2LXvyriXOH8mwdWBcjOviVamvFQNtI1d9wyTGLW1CK-UcXWnKaH-f3eX0=), [Facebook](https://www.globenewswire.com/Tracker?data=MoP02pip5Ac2Frh7Blv2rA911PKPzplP92_Vi7i2Qj8sS6z_Rogv430XhH10RY7FJmdirOD8gJaYikbQApks8HNcJesmjNlnXXB3pShVoEk=), [Instagram](https://www.globenewswire.com/Tracker?data=eyapK56l54DePaWnxXaGyABGIrf8EM2XFYYPx1u4cKSLreiZx9sbV1mV7ifSLK_iUKgXg71ONnKuaLGREDkLS_gOadXoIOfv5hgsxiAcsnE=), and [YouTube](https://www.globenewswire.com/Tracker?data=NfJyZ6xUiogzE3VgzymoSRq8-vNhfSaXciFT3Zz-IJK7tubkVJfzzcZ_wMshLiOBmFccmTdSD45JdoRPVgEJbVUtFNt-L-eEIz-HnNhXKL0=).

![](https://www.globenewswire.com/newsroom/ti?nf=MTAwMTEyMTY1OSM0MDIxOTQ2OTMjMjIzMzgzMw==)  

![](https://ml-eu.globenewswire.com/media/MzRkMmExYTUtMTE0Mi00ZDEyLTgzNTAtZGU3ZDhlYTJkNWQ3LTEyNDUzODYtMjAyNS0wOC0wNi1lbg==/tiny/Alvotech.png)